

# **SUPPRESSION AND ACTIVATION OF LIPID SIGNALLING IN CANCER: TUMOUR SUPPRESSOR PTEN AND ONCOGENIC SPHINGOSINE KINASE**

**A thesis submitted in fulfilment of the requirements of the degree of Doctor of  
Philosophy**

Submitted by

Nahal Haddadi

(BSc, MSc (MedBiotech))

**School of Life Sciences, Faculty of Science  
University of Technology Sydney, Australia**

2019

## CERTIFICATE OF ORIGINAL AUTHORSHIP

I, Nahal Haddadi declare that this thesis, is submitted in fulfilment of the requirements for the award of Doctor of Philosophy, in the Faculty of Science at the University of Technology Sydney.

This thesis is wholly my own work unless otherwise reference or acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

This document has not been submitted for qualifications at any other academic institution.

This research is supported by the Australian Government Research Training Program.

Signature:

Production Note:  
Signature removed prior to publication.

Date: 13/06/2019

## ACKNOWLEDGEMENTS

---

I would like to express my sincere gratitude to a few special people in my life, without whose help, encouragement and guidance, the completion of this study would not have been possible.

I am grateful to my supervisors, Dr Najah Nassif, Dr Eileen McGowan and Dr Yiguang Lin, for their help, support and supervision during my postgraduate studies.

I would like to thank our collaborators from China, Dr Hongjie Chen, Dr Qiuxia Li, Dr Meijun Long and Prof Xiaofeng Zhu from the 3rd Affiliated Hospital of Sun Yat-sen University, who provided access to human clinical samples and helped in their processing in the second part of this thesis.

I owe my deepest gratitude to my father and mother, for their unconditional love, care and support. Although there are miles between us, we are never far apart. I can never thank you enough for what you have done for me. I would also like to thank my siblings Naghmeh and Navid, for their concern, kind words and support.

I would like to show my gratitude to my best friend and companion Oliver John Santos. Thanks for your constant support and encouragement. Thanks for always being there for me in hardship.

I am grateful to Maria Santos for her kind support and prayers.

I would like to thank my PhD colleagues Diana Hatoum and Chwee Fern Bok for their help in optimisation of PCR and initial work on SphK1, and I would like to thank Shohreh Razavy for her guidance in statistical analysis and Dr Sarah Bajan for her technical support.

I want to express my gratitude to the University of Technology Sydney for the award of an International Research Scholarship for the period of my PhD candidature.

## LIST OF PUBLICATIONS AND PRESENTATIONS

### JOURNAL ARTICLES

1. Haddadi N, Lin Y, Travis G, Simpson AM, Nassif NT, McGowen E: **PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.** *Mol Cancer* 2018, **17**:37.
2. Haddadi N, Lin Y, Simpson AM, Nassif NT, McGowan EM: **"Dicing and Splicing" Sphingosine Kinase and Relevance to Cancer.** *Int J Mol Sci* 2017, **18**.
3. Hatoum D, Haddadi N, Lin Y, Nassif NT, McGowan EM: **Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget.** *Oncotarget* 2017, **8**:36898-36929.
4. Haddadi N\*, Chen H\*, Li Q\*, Long M, Hatoum D, Bok CF, Zhu X, Nassif NT, Lin Y, McGowan EM: **Differential expression of sphingosine kinase 1 major Isoforms in human cancer patients and cancer cell lines: implications for cancer therapy.** (Submitted to Cancers).
5. Haddadi, N, Lin Y, McGowan, EM and Nassif, NT: **Cancer-associated mutations of PTEN alter PTEN function.** (Manuscript in preparation 2019).

### PUBLISHED ABSTRACTS AND CONFERENCE PRESENTATIONS

1. Nahal Haddadi, Eileen McGowan, and Najah Nassif. Alteration Cellular Function by Cancer-associated Mutations of PTEN. **Frontiers in Cancer Science (FCS) 2017, Singapore.**

2. Nahal Haddadi, Eileen McGowan, and Najah Nassif. Cancer-Associated PTEN Mutations Alter PTEN Cellular Function. **Australasian Genomic Technologies Conference (AGTA) 2017, Hobart, TAS.**
3. Nahal Haddadi, Eileen McGowan, and Najah Nassif, Determining the Frequency and Involvement of PTEN Pseudogene (PTENP1) Expression in Cancer Cell Lines. **New Horizons Conference 2015, Sydney, NSW.**

### **AWARDS AND RECOGNITION**

Recipient of UTS International Research Scholarship (UTS IRS), University of Technology Sydney (2015-2018).

## **LIST OF ABBREVIATIONS**

Ab	Antibody
Amp	Ampicillin
AKT	AKT/protein kinase B
ATP	Adenosine triphosphate
BAD	Bcl-2 associated death promoter
Bp	Base pairs
BSA	Bovine serum albumin
Caspase	Cystein aspartate specific proteases
CBF1	Also known as recombination signal binding protein for immunoglobulin kappa J region (RBBJ)
cGMP	Cyclic guanosine monophosphate
CK	Creatine kinase
CK2	Casein kinase II
CMV	Cytomegalovirus
CO <sub>2</sub>	Carbon dioxide
cDNA	Complementary DNA
CRC	Colorectal Cancer
CDK	Cyclin dependent kinase
DMEM	Dulbecco's Modified Eagle's Medium
DMSO	Dimethyl sulfoxide
dNTPs	deoxynucleotide triphosphates
DNA	Deoxyribonucleic acid
EDTA	Ethylenediaminetetraacetic acid
FCS	Foetal calf serum
Kb	Kilobase
MW	Molecular weight
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
PI	Propidium iodide

PIP2	Phosphoinositide 3,4,5-triphosphate
PIP3	Phosphoinositide 4,5-bisphosphate
PTEN	Phosphatase and tensin homologue deleted on chromosome 10
RNA	Ribonucleic acid
Tris	2-amino-2(hydroxymethyl-1,3-propanediol)

## ABSTRACT

The *PTEN* tumour suppressor is the second most frequently mutated tumour suppressor gene in cancer. It is a lipid and protein phosphatase that negatively regulates the well-known pro-proliferative and anti-apoptotic phosphatidylinositol 3-kinase (PI3K)/AKT signalling pathway to modulate cell proliferation, cell cycle progression and cell survival. Sphingosine kinase 1 (SphK1), a known tumour promoter/oncogene, has been shown to activate the PI3K/Akt pathway to enhance resistance to apoptosis. The loss of function of *PTEN* and/or the overexpression of SphK1 contribute to tumorigenesis. This thesis describes the analysis of novel, cancer associated mutations of *PTEN*, to determine their effect(s) on wild type (WT) *PTEN* function, and also explores differential SphK1 isoform expression in cancers.

Previous work in our laboratory described 10 novel somatic mutations of *PTEN* in primary colorectal tumours. To determine the functional consequences of these novel cancer-associated *PTEN* mutations, the WT *PTEN* and the series of *PTEN* mutants (K62R, Y65C, K125E, K125X, E150Q, D153N, D153Y, N323K and the C124S and G129E controls) were transiently transfected into: (A) *PTEN* null U87MG glioblastoma cells, and WT *PTEN* expressing (A) HCT116 colon cancer and (C) MCF7 breast cancer cells. Transfected cells were then assayed for cell proliferation, cell cycle phase distribution and AKT phosphorylation. In U87MG cells, 50% of the *PTEN* mutants (Y65C, K125E, E150Q and D153Y) exhibited statistically significant reductions in cell proliferation, but not to the level of that of WT *PTEN*. In both the HCT116 and MCF7 cell lines, 80% of the *PTEN* mutants (K62R, Y65C, K125E, K125X, E150Q, D153Y and N323K) displayed reduced cell proliferation rates but none produced reductions comparable with WT *PTEN*. Further, relative to WT *PTEN*, 75% of *PTEN* mutants (K62R, K125X, E150Q, D153N and N323K) possessed functional deficiency in cell cycle inhibitory capacity in the G2 phase in U87MG cells. In contrast, 90% of *PTEN* mutants (K62R, K125E, K125X, E150Q, D153N, D153Y and N323K) possessed functional deficiency in the cell cycle inhibitory capacity in either the G1 or G2 phase in HCT116 cells. In MCF7 cells, 100% and 60% (K62R, Y65C, D153N, D153Y and N323K) of the *PTEN* mutants had functional deficiency in cell cycle inhibitory capacity in either the G1 or G2 phase, respectively. The analyses of endogenous suppression of phosphorylation of AKT revealed that 40% of *PTEN* mutants (K125E, K125X and D153N) show deficiency in pAKT suppression in the U87MG cell line while 60% of the mutants showed such deficiency in the HCT116 cell line (K125X, E150Q, D153N, D153Y and N323K). All but one (K62R) of the *PTEN* mutants showed a deficiency in the ability to suppress the level of endogenous phosphorylated AKT in the MCF7 cells. Overall, the results of the functional assays showed that the somatic mutations of the *PTEN* gene alter *PTEN* tumour suppressor function.

Expression of SphK1, a positive upstream regulator of the Akt pathway, is expressed as 2 major isoforms, SphK1-43kDa (SphK1a) and SphK1-51kDa (SphK1b), with similar SphK1 activity. However, to date, there is no literature on the expression of the two SphK1 isoforms in cell lines or human tissues. Profiling the expression of the two SphK isoforms in various cancer cell lines (n=24), primary cancer tissues (n=28) and paired adjacent tissues (n=28), demonstrated that the SphK1a isoform is expressed in all cell lines and tissues (both normal and cancer) studied, however, expression of SphK1b is cell and tissue specific, including breast, prostate and lung. Balancing signalling pathways and maintaining cellular homeostasis, as observed through the *PTEN*/SphK1 swinging pendulum is important and the study of these pathways is crucial in gaining further understanding the opposing regulatory mechanisms, which may be exploited for the future prevention and treatment of cancers.



## TABLE OF CONTENTS

General Introduction.....	1
<b>CHAPTER 1 .....</b>	<b>4</b>
1.1 PTEN: an overview .....	6
1.2 PTEN Gene and Protein Structure.....	9
1.3 Cellular functions of PTEN.....	12
1.3.1 The cytoplasmic role(s) of PTEN.....	12
1.3.1.1 The PI3K pathway and regulation of cell proliferation and apoptosis .....	12
1.3.1.2 The role of PTEN in cell migration.....	13
1.3.1.3 Role of PTEN in tumour angiogenesis.....	16
1.3.2 The roles of PTEN in the nucleus .....	17
1.3.3 PTEN nucleocytoplasmic translocation.....	19
1.4 Involvement of PTEN in disease.....	19
1.4.1 Germline PTEN mutation and the PTEN hamartoma tumour syndromes.....	19
1.4.2 PTEN Somatic mutation and tumorigenesis .....	22
1.5 Regulation of PTEN cellular abundance and activity .....	25
1.5.1 Transcriptional regulation of PTEN .....	25
1.5.2 Post transcriptional regulation of PTEN by microRNAs and PTENP1 .....	27
1.5.2.1 Post-transcriptional regulation of PTEN by microRNAs.....	28
1.5.2.2 Regulation of PTEN abundance by PTENP1 .....	30
1.5.3 Regulation of PTEN by post-translational mechanisms.....	32
1.5.3.1 Regulation of PTEN by phosphorylation. ....	32
1.5.3.2 Regulation of PTEN by acetylation.....	32
1.5.3.3 Regulation of PTEN by oxidation.....	34
1.5.3.4 Regulation of PTEN by ubiquitination.....	34
1.6 Background to the project and aims.....	34
1.6.1 Project objectives.....	38
<b>CHAPTER 2 .....</b>	<b>39</b>
<b>GENERAL MATERIALS AND METHODS.....</b>	<b>39</b>
2.1.1 Cell lines .....	40
2.1.2 Antibodies and stains .....	41
2.1.4 Protein molecular weight standards.....	41

2.2 General methods.....	42
2.2.1 Sterility and containment of biological materials .....	42
2.2.2 Measurement of nucleic acid concentration .....	42
2.2.3 Agarose gel electrophoresis .....	42
2.2.4 Preparation and growth of plasmid clones.....	43
2.2.4.1 Bacterial growth and maintenance.....	43
2.2.5 Preparation of plasmid DNA .....	43
2.2.5.1 Small scale preparation (mini-prep) of plasmid DNA .....	43
2.2.5.2 Large scale preparation (midi-prep and maxi-prep) of plasmid DNA.....	44
2.2.6 Tissue culture methods .....	44
2.2.6.1 Tissue culture materials .....	44
2.2.6.2 Maintenance of human cancer cell lines .....	44
2.2.6.3 Determining cell growth characteristics and growth curve preparation .....	45
2.2.6.4 Determination of cancer cell doubling time .....	45
2.2.6.5 Preparation of frozen cell stocks.....	45
2.2.7 Methods for the preparation and analysis of RNA .....	46
2.2.7.1 Isolation of total RNA from cell lines .....	46
2.2.8 Reverse transcription and synthesis of cDNA .....	47
2.2.9 Polymerase chain reaction (PCR) .....	47
2.2.10 Protein analysis methods .....	48
2.2.10.1 Materials for protein analysis .....	48
2.2.10.2 Protein extraction for western blotting.....	48
2.2.10.3 Polyacrylamide gel electrophoresis of proteins.....	48
2.2.10.4 Western blot analysis.....	49
2.2.11 Software and bioinformatics.....	50
2.2.12 Statistics .....	50
<b>CHAPTER 3 .....</b>	<b>52</b>
3.1 Introduction .....	53
3.2 Materials and methods .....	54
3.2.1 Cloning vectors and bacterial Host Strains .....	54
3.2.1.1 Verification of PTEN expression construct sequences.....	55
3.2.2 Transfection protocols and cellular analysis: optimisation and pilot analysis .....	55
3.2.2.1 Optimisation of transfection efficiency by flow cytometry.....	55

3.2.2.2 Optimising transfection parameters for transient transfection in 6 well plates .....	56
3.2.2.3 Optimising transfection parameters for transient transfection in 96-well plates .....	56
3.2.3 Determining the seeding density of individual cancer cell lines for the SYBR green-based cell proliferation assay .....	57
3.3 Results .....	58
3.3.1 Verification of wild type (WT) and mutant PTEN sequences.....	58
3.3.2 Optimal cell seeding density for cell proliferation analysis differs for the different cell lines.....	58
3.3.3 Optimal cell seeding density for cell proliferation analysis differs for the different cell lines.....	61
3.4 DNA and Lipofectamine concentrations were determined for optimal transfection efficiency .....	63
3.4.1 Verification PTEN expression status of cancer cell lines.....	67
3.4.2 Verification of PTEN expression post transfection .....	67
3.4.3 Summary .....	70
<b>CHAPTER 4</b> .....	<b>71</b>
4.1 Introduction .....	72
4.2 Specific materials and methods .....	73
4.2.1 Analysis of cancer cell proliferation using a SYBR Green based assay.....	73
4.3 RESULTS 1: DETERMINING THE EFFECT OF WILD TYPE AND MUTANT PTEN ON THE PROLIFERATION OF CANCER CELLS .....	77
4.3.1 Background .....	77
4.3.2 Mutant PTEN decreases U87MG glioblastoma cell proliferation with reduced efficacy compared to wild type PTEN .....	79
4.3.3 The effect of wild type and mutant PTEN on the proliferation of HCT116 colon cancer cells.....	83
4.3.4 The effect of wild type and mutant PTEN on the proliferation of MCF7 breast cancer cells.....	87
4.4 RESULTS 2: DETERMINING THE EFFECT OF WILD TYPE AND MUTANT PTEN ON THE CELL CYCLE PHASE DISTRIBUTION OF CANCER CELLS .....	92
4.4.1 Introduction and background .....	92
4.4.2 Effect of expression of wild type and mutant PTEN on the cell cycle phase distribution of U87MG glioblastoma cells .....	94
4.4.3 Effect of expression of wild type and mutant PTEN on the on the cell cycle phase distribution of HCT116 colon cancer cells .....	98

4.4.4 Effect of expression of wild type and mutant PTEN on the on the cell cycle phase distribution of MCF7 breast cancer cells .....	101
4.5 RESULT 3: DETERMINING THE EFFECT OF WILD TYPE AND MUTANT PTEN ON AKT PHOSPHORYLATION IN CANCER CELLS .....	105
4.5.1 Background.....	105
4.5.2 Expression of mutant PTEN suppresses AKT phosphorylation with reduced efficacy compared to wild type PTEN in U87MG glioblastoma cells .....	107
4.5.3 Expression of mutant PTEN suppresses AKT phosphorylation with reduced efficacy compared to wild type PTEN in HCT116 cells.....	108
4.5.4 Expression of mutant PTEN suppresses AKT phosphorylation with reduced efficacy compared to wild type PTEN in MCF7 breast cancer cells .....	110
4.6 DISCUSSION .....	114
4.6.1 Effect of wild type and mutant PTEN on cancer cell proliferation .....	115
4.6.2 Effect of wild type and mutant PTEN expression on the cell cycle phase distribution of cancer cells (U87MG, HCT116 and MCF7) .....	122
4.6.3 Effect of wild type and mutant PTEN expression on AKT phosphorylation of cancer cells (U87MG, HCT116 and MCF7) .....	125
<b>CHAPTER 5 .....</b>	<b>130</b>
5.1 SphK1: an overview .....	133
5.2 Importance of isoenzymes (isozymes) and variant isoforms in the future of Cancer treatment .....	135
5.3 SphK isozymes and isoforms .....	137
5.3.1 Clarification of sphk nomenclature.....	137
5.3.2 SphK1 and SphK2 isozymes are transcribed from different genes and evolutionary conserved .....	139
5.4 Lessons from the SphK 'Isozyme' knockout mouse models from mouse to human .....	142
5.5 SphK1 and SphK2 isozymes transcribe multiple variant isoforms .....	145
5.6 SphK1 variant isoforms—differences in dicing, splicing and localisation.....	146
5.7 Over-active sphk-s1p signalling and relevance to cancer .....	147
5.8 SphK1 isozyme is overexpressed in multiple cancer types.....	150
5.9 'Dicing and splicing' sphingosine kinase variant isoforms and relevance to cancer .....	150
5.10 Homing into SphK1 isoform expression in anti-cancer targets .....	151
5.11 Aims of the study .....	152
<b>CHAPTER 6 .....</b>	<b>153</b>
6.1 Introduction .....	154

6.2 Methods and Results.....	154
6.2.1 SphK1 isoform expression in MCF7 stable cell lines .....	154
6.2.2 Optimisation of PCR parameters.....	155
6.2.2.1 Optimisation of the SphK1-PCR primers .....	155
6.3 Summary and conclusion .....	159
<b>CHAPTER 7 .....</b>	<b>161</b>
7.1 Introduction.....	162
7.2 Methods .....	164
7.2.1 Cell culture. ....	164
7.2.2 Cell lines .....	164
7.2.3 Clinical tissue samples:.....	166
7.2.4 RT-PCR amplification .....	166
7.3 Results .....	167
7.3.1 Only SphK1a isoform is expressed in hepatocellular carcinoma patient tissue in vivo .....	170
7.3.2 Differential expression of SphK1a and SphK1b isoforms in prostate cancer patient tissue in vivo .....	174
7.3.3 Differential SphK1 isoform expression by RT-PCR in breast cancer patients. ....	177
7.4.1 SphK1 isoform mRNA stability .....	182
7.5 Discussion.....	184
<b>CHAPTER 8 .....</b>	<b>188</b>
8.1 The effect of PTEN mutations on the suppressive functions of PTEN .....	189
8.2 Profiling SphK1 isoform expression in cancer cells and primary human cancer tissues.....	191
<b>Appendix-I.....</b>	<b>194</b>
<b>Appendix II.....</b>	<b>201</b>
<b>REFERENCES.....</b>	<b>206</b>

## LIST OF FIGURES

Figure 1.0 PTEN and SphK1 are opposing regulators of the PI3K/AKT Pathway .....	2
Figure 1.1 PTEN is a major negative regulator of the PI3K pathway .....	8
Figure 1.2 PTEN domain and 3D structure. ....	11
Figure 1.3 Role of PTEN in the PI3K/Akt signalling pathway .....	14
Figure 1.4 Cellular functions mediated by PTEN lipid and protein phosphatase activities .....	15
Figure 1.5 The cytoplasmic and nuclear functions of PTEN .....	18
Figure 1.6 Regulation of PTEN, a major regulator of the PI3K/AKT signalling pathway .....	26
Figure 1.7 Regulation of protein coding mRNAs by miRNAs .....	29
Figure 1.8 Post-transcriptional regulation of PTEN by miRNAs and PTENP1 .....	31
Figure 1.9 PTEN protein domain structure and sites of post-translational modification .....	33
Figure 1.10 Somatic mutations of PTEN detected in primary sporadic colorectal tumours. ....	36
Figure 3.1 WT and mutant PTEN expression construct sequence verification.....	59
Figure 3.2 Determining optimal cell seeding densities for U87MG, HCT116 and MCF7 cells.....	62
Figure 3.3 Determining parameters for optimal transfection efficiency .....	64
Figure 3.4 Optimising transfection efficiency for PTEN functional and cellular analysis .....	66
Figure 3.5 Detection of both endogenously, and exogenously, expressed PTEN by western analysis. ....	68
Figure 3.6 Detection of exogenously expressed wild type and mutant PTEN in U87MG cells by western analysis .....	69
Figure 4.1 PTEN is a negative regulator of cell proliferation .....	78
Figure 4.2 Analysis of cell proliferation rate of U87MG glioblastoma cells transfected with wild type and mutant PTEN .....	82
Figure 4.3 Analysis of cell proliferation rate of HCT116 colon cancer cells transfected with wild type and mutant PTEN .....	86
Figure 4.4 Analysis of cell proliferation rate of MCF7 breast cancer cells transfected with wild type and mutant PTEN .....	90
Figure 4.5 The cell cycle and the role of PTEN in cell cycle regulation .....	93
Figure 4.6 Cell cycle analysis of transfected U87MG cells using ModFIT software. ....	95
Figure 4.7 Cell cycle phase distribution of wild type and mutant PTEN expressing U87MG glioblastoma cells .....	96
Figure 4.8 Cell cycle phase distribution of wild type and mutant PTEN expressing HCT116 colon cancer cells.....	99
Figure 4.9 Cell cycle phase distribution of wild type and mutant PTEN expressing MCF7 breast cancer cells.....	102
Figure 4.10 PTEN is a negative regulator of the PI3K/AKT pathway through dephosphorylation of PIP3. ....	106
Figure 4.11 The effect of wild type and mutant PTEN expression on the phosphorylation of AKT in U87MG glioblastoma cells.....	108
Figure 4.12 The effect of wild type and mutant PTEN expression on the phosphorylation of AKT in HCT116 colon cancer cells .....	110

Figure 4.13 The effect of wild type and mutant PTEN expression on the phosphorylation of AKT in MCF7 breast cancer cells .....	112
Figure 4.14 Location of the cancer-associated mutations of PTEN within the PTEN protein sequence and domain structure. ....	124
Figure 5.1 PTEN and SphK1 are opposing regulators of the PI3K/AKT Pathway. ....	133
Figure 6.1. Verification of expression of exogenous SphK1a and SphK1b in stably MCF7 transfected cells by western blot .....	155
Figure 6.2 SphK1 forward and reverse PCR primer sequences and locations.....	157
Figure 6.3. Optimisation and selection of SphK1 isoform PCR primers.....	158
Figure 6.4 SphK1 ‘Bermuda triangle’ .....	159
Figure 6.5 MCF-7 cells express both SphK1b and SphK1 isoforms .....	160
Figure 7.1 SphK1 is not a predictor of RFS in all cancers.....	162
Figure 7.2 Differential expression of SphK1 isoform in cancer cells <i>in vitro</i> .....	168
Figure 7.3 Comparative analysis of SphK1a and SphK1b isoform expression in liver cancer and adjacent samples.....	172
Figure 7.4 Comparative analysis of SphK1a and SphK1b isoform expression in prostate cancer and adjacent samples .....	175
Figure 7.5 Comparative analysis of SphK1a and SphK1b isoform expression in breast cancer and adjacent samples .....	178
Figure 7.6 Predicted secondary structure of SphK1a and SphK1b based on the lowest free energy structure .....	183
Figure 8.1 PTEN Suppresses and SphK1 Activates the PI3K/AKT Pathway .....	190

## LIST OF TABLES

Table 1.1 Frequency of <i>PTEN</i> mutation, deletion and loss of <i>PTEN</i> expression in various sporadic tumour types.....	24
Table 1.2 <i>PTEN</i> -targeting miRNAs identified in various cancer types. ....	29
Table 1.3 Summary of the properties of each of the 10 novel cancer-associated <i>PTEN</i> mutations to be studied in this project.....	37
Table 4.1 Comparison of the effect of wild type or mutant <i>PTEN</i> on the cell proliferation of U87MG, HCT116 and MCF7 cells.....	91
Table 4.2 Comparison of the G1 and G2 cell cycle phase distribution of WT and mutant <i>PTEN</i> transfected U87MG cells.....	97
Table 4.3 Comparison of the G1 and G2 cell cycle phase distribution of WT and mutant <i>PTEN</i> transfected HCT116 cells.....	100
Table 4.4 Comparison of the G1 and G2 cell cycle phase distribution of WT and mutant <i>PTEN</i> transfected MCF7 cells.....	103
Table 4.5 Summary of the effect of wild type and mutant <i>PTEN</i> on the cell cycle distribution in cancer cells.....	104
Table 4.6 Summary of the effect of wild type and mutant <i>PTEN</i> on the level of pAKT in cancer cells.....	113
Table 4.7 Summary of results of the functional effects of the different <i>PTEN</i> mutations on the functions of <i>PTEN</i> in the regulation of cell proliferation, the cell cycle and AKT phosphorylation status in cancer cells (U87MG, HCT116 and MCF7) .....	116
Table 5.1 Overexpression of SphK is causally linked to cancer.....	136
Table 5.2 Nomenclature of SphK1 and SphK2 isozymes and protein isoforms.....	138
Table 5.3 SphK inhibitors tested in human cancer cells and primary human cancer cells.....	148
Table 7.1 Cell lines used for the identification of SphK1 isoforms.....	165
Table 7.2 Comparison of SphK1a- and SphK1b -PCR products in cancer cell lines. ....	169
Table 7.3 Characteristics and expression of SphK1 isoform expression in liver cancer patients..	170
Table 7.4 SphK1 isoform expression in liver cancer patients. ....	173
Table 7.5 Characteristics of Prostate Cancer Samples .....	174
Table 7.6 SphK1 isoform expression in prostate cancer clinical samples.....	176
Table 7.7 Characteristics of Breast Cancer Samples .....	177
Table 7.8 SphK1 isoform expression in breast cancer clinical samples .....	180
Table 7.9 Analysis of SphK1 isoform expression in breast cancer patients by Grade.....	181
Table 7.10 Analysis of SphK1 isoform expression in breast cancer patients by hormonal status.....	181